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ABSTRACT:
Repair of double strand DNA breaks (DSBs) is pivotal in maintaining normal 
cell division and disruption of this system has been shown to be a key factor in 
carcinogenesis. Loss of expression of the DSB repair proteins have previously been 
shown to be associated with poorer survival in colorectal cancer. We wished to 
ascertain the relationship of altered expression of the DSB repair proteins γ-H2AX 
(gamma-H2AX), ATM and Ku70 with biological and clinico-pathological features 
of colorectal cancer. 908 tumours from the VICTOR clinical trial of stage II/III 
colorectal cancer were analysed for expression of γ-H2AX, ATM and Ku70 using 
immunohistochemistry. Expression levels were correlated with CIN and with disease-
free survival, correcting for microsatellite instability, BRAF/KRAS mutation status, 
Dukes stage, chemo/radiotherapy, age, gender and tumour location.  Down-regulated 
Ku70 expression was associated with chromosomal instability (p=0.029) in colorectal 
cancer. Reduced ATM expression was an independent marker of poor disease-free 
survival (HR=1.67, 95% CI 1.11-2.50, p=0.015).  For Ku70, further studies are 
required to investigate the potential relationship of non-homologous end joining with 
chromosomal instability.  Loss of ATM expression might serve as a biomarker of poor 
prognosis in colorectal cancer.  
INTRODUCTION
Repair of DNA double-strand breaks (DSBs) by 
non-homologous end joining (NHEJ) is essential in 
maintaining DNA integrity [1]. The proteins that play 
a pivotal role in this process are ataxia telangiectasia-
mutated (ATM), the histone γ-H2AX and the Ku70/
Ku80 complex. Defective DSB repair may contribute 
to the chromosome instability (CIN) phenotype in 
cancer [1]. Although poorly defined, CIN is generally 
used as shorthand for cancers with polyploidy, grossly 
abnormal chromosome number and multiple structural 
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abnormalities.
H2AX is a member of the histone H2A family that 
helps to package and organise DNA into chromatin, the 
basic subunit of which is the nucleosome [2]. ATM is a 
serine-threonine kinase that is activated by DSBs and 
activates several downstream targets, including those 
involved in DNA repair.  It is also, however, involved in 
induction of cell senescence and apoptosis [3]. ATM and 
the related proteins ataxia telangiectasia Rad-3 related 
(ATR) and DNA-dependent protein kinase (DNA-PK) 
are activated immediately when a double-strand DNA 
break occurs. These then act to phosphorylate H2AX at 
its fourth serine residue, a species that is termed γ-H2AX 
(gamma-H2AX) [2]. ATM activation is mediated by 
autophosphorylation of the serine residue at position 
1981 in the ATM protein [4]. This is in turn mediated 
by mobilisation of the Rad50/MRE complex.g-H2AX 
then binds near the site of the DSB and enters a signal 
amplification loop. NBS1 (Nijmegen breakage syndrome 
protein 1) and MDC1 (Mediator of DNA damage 
checkpoint protein 1) – both directly involved in DSB 
repair – are recruited, stimulate ATM expression and 
further increase H2AX phosphorylation and recruitment 
[5]. The bound NBS1 then goes on to activate DSB repair, 
which can occur via either homologous recombination 
(HR) or non-homologous end joining (NHEJ). γ-H2AX 
also has several roles in regulating apoptosis, presumably 
if DSB repair fails [6]. Ku70 and Ku80 form the Ku 
heterodimer complex that binds to the site of DSB and 
aids in NHEJ.
Few studies have examined the expression of DSB 
repair proteins in colorectal carcinogenesis, in particular 
their relationships with chromosomal instability (CIN) 
or association with patient outcome. Grabsch et al 
[7] analysed 342 colorectal cancers for expression of 
ATM, BRCA1, BRCA2, Ku70 and Ku80. They found 
that patients whose tumours had normal expression of 
BRCA1 or ATM had significantly longer survival, with 
ATM being an independent prognostic marker. Rigas et 
al [8] found reduced expression of Ku70/80 in colorectal 
adenomas. Komuro et al [9] found that relatively high 
Ku70/80 expression was associated with longer disease-
free survival and increased radiosensitivity in a set of 96 
rectal cancers. No previous studies have examined the role 
of γ-H2AX in colorectal cancer in this way, and none that 
have compared DSB repair protein expression with the 
presence of CIN.
In this study, we examined the expression of 
g-H2AX, ATM and Ku70 in a set of 908 stage II/
III colorectal cancers. We searched for associations 
between DSB repair protein expression and chromosomal 
instability (CIN). Finally, we tested each protein as a 
marker of prognosis.
RESULTS
γ-H2AX, ATM and Ku70 expression
A total of 2,821 tissue cores from 908 cancers on 
24 tissue microarrays were available from the VICTOR 
study. Owing to tissue loss during the IHC process and 
limited availability of some blocks, all cores were stained 
Table 1: Comparison of DSB seen vs presence 
of chromosomal instability demonstrated by 
ploidy status, demonstrating no relationship 
between number of double strand breaks seen 
and chromosomal instability status
Double stranded breaks
γ-H2AX p
Absent Present Total 0.66
CIN+ 143 115 258
CIN- 100 87 187
Total 243 202 445
ATM
Absent Present Total 0.91
CIN+ 52 107 159
CIN- 103 207 310
Total 158 314 469
Ku70
Absent Present Total 0.029
CIN+ 20 65 85
CIN- 54 90 144
Total 74 155 229
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for g-H2AX, 2464 for ATM and 1195 for Ku70. Because 
of this, not every case had three evaluable cores. Image 
cytometry was performed on 469 of the 908 cancers: for 
γ-H2AX, 385 tumours with both IHC and ploidy analysis 
were successfully analysed; for ATM, 394 tumours were 
studied; and for Ku70, 204 tumours were analysed.  
In order to determine the baseline level of γ-H2AX 
expression and therefore, by inference, double strand 
breaks (DSB), nuclear expression of γ-H2AX was 
initially assessed in 411 normal tissue cores from different 
patients. None of the samples showed nuclear g-H2AX 
expression. Of the 908 carcinomas, 440/908 (48.5%) 
had nuclear γ-H2AX expression. For ATM, 537/908 
(59.1%) cancers had reduced/absent expression compared 
to normal mucosa and for Ku70, 443/908 (48.8%) 
cancers had reduced/absent expression. There was no 
association between the expression levels of H2AX and 
ATM (χ21=0.43, p=0.51), H2AX and Ku70 (χ
2
1=0.0013, 
p=0.971) or ATM and Ku70 (χ21=1.65, p=0.20). Inter-
observer agreement was high in all cases (for γ-H2AX, 
Spearman’s ρ=0.71, p<0.001; for ATM, ρ=0.80, p<0.001); 
and for Ku70,ρ= 0.89, p<0.001).
DSB repair protein expression, CIN and 
clinicopathological variables
We tested for associations between DSB repair 
protein expression and CIN (Table 1). Evidence of an 
association was found between loss of expression of Ku70 
and CIN (χ21=4.77, p=0.029), but none was found for 
γ-H2AX (χ21=0.23, p=0.63) or ATM (χ
2
1=0.013, p=0.91). 
We also tested expression of each protein against all other 
clinicopathological variables (age, gender, Dukes stage, 
post-operative chemotherapy, pre-operative radiotherapy, 
site of tumour, KRAS mutation status, BRAF mutation 
status, MSI and trial group, i.e. placebo/rofecoxib). 
There was no significant association after correcting 
for multiple testing (p>4.53x10-3 in all cases), and there 
was specifically no association between DSB protein 
expression and rofecoxib therapy during the trial. 
DSB protein expression and prognosis
In total, 2,434 people were recruited to the VICTOR 
trial. Patients were randomly assigned in a double blind 
fashion to the trial at a variable time (mean 193 days, 
range 4-386 days) after completing definitive treatment 
(surgery and/or chemo/radiotherapy). 1,217 individuals 
were randomised to the rofecoxib arm (one 25mg tablet of 
rofecoxib daily) of the trial and 1,217 to the placebo arm. 
Of the 908 patients available for this study, the average 
overall survival (OS) was 4.81 years (range 0.3-7.86 
years) and the average disease-free survival (DFS) was 
3.36 years (range 0.3-7.86 years).
Kaplan-Meier plots of disease-free survival (DFS) 
by g-H2AX, ATM and Ku70 status are shown in Figure 
1. Univariate Cox regression modelling showed that 
worse survival was associated with reduced expression of 
ATM  in tumours as compared to normal tissue (HR=1.56, 
Figure 1: Kaplan-Meier plots showing relationship 
between disease free survival and g-H2AX, ATM and 
Ku70 expression
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95% CI 1.05-2.33, p=0.028). No significant associations 
were found between survival and expression of g-H2AX 
(HR=1.23, 95% CI 0.83-1.82, p=0.30) and Ku70 
(HR=1.41, 95% CI 0.91-2.13, p=0.12). We also found no 
association between loss of Ku70 expression and disease 
free survival within the CIN tumour group (HR 1.42, 95% 
CI 0.59-3.44, p=0.433) in a univariate model. 
We then performed multivariate reverse stepwise 
Cox regression modelling (with a threshold for removal 
from the model of p>0.05) for each of g-H2AX, ATM 
and Ku70, including as co-variates age, gender, Dukes 
stage, tumour location, trial arm (rofecoxib vs. placebo), 
chemotherapy status, radiotherapy status, CIN, KRAS 
and BRAF mutation status and MSI (Table 2). Reduced 
expression of ATM remained associated with DFS 
(HR=1.67, 95% CI 1.11-2.50, p=0.015), as was Dukes 
stage C (HR=2.53, 95% CI 1.55-4.11, p<0.001). Neither 
g-H2AX nor Ku70 expression was associated with DFS in 
the multivariate model (details not shown). In univariate 
analysis we found that chemotherapy (HR 0.50, 95% CI 
0.35-0.72, p<0.001) was associated with better DFS, but 
not radiotherapy (HR 0.68, 95% CI 0.44-1.05, p=0.086) 
probably due to the small numbers of patients undergoing 
radiotherapy.  
In order to explore whether there was a single 
model that could be derived based on a combination 
of the expression levels of all DSB repair proteins, a 
multivariate reverse stepwise Cox regression model was 
constructed with the following variables: γ-H2AX, ATM, 
Ku70 and the above co-variates. Loss of ATM expression 
was independently associated with DFS (HR=1.92, 95% 
CI 1.03-3.57, p=0.003) as well as Dukes C stage (HR 
2.34, 95% CI 1.43-3.83, p=0.001). For comparison, the 
same analysis was carried out for overall survival, but no 
variable was a significant predictor of outcome, perhaps 
owing to fewer events. 
Finally, in order to explore whether DSB repair 
protein expression was related to response to radiotherapy 
and chemotherapy as measured by DFS, all patients 
undergoing radiotherapy (n=68) and chemotherapy 
(n=436) were analysed via a univariate Cox regression 
model. In the radiotherapy group, there was a tendency 
towards longer DFS in patients with loss of expression 
of g-H2AX however there was no significant relationship 
between disease free survival and loss of expression of 
γ-H2AX (HR=2.92, 95% CI 0.94-9.14, p=0.064), ATM 
(HR=1.78, 95% CI 0.63-5.03, p=0.28) or Ku70 (HR=0.58, 
95% CI 0.07-4.98,p=0.62).   In the chemotherapy group, 
there was no significant associations between disease free 
survival and loss of expression of γ-H2AX (HR 1.28, 95% 
CI 0.82-2.00, p=0.277), ATM (HR 1.52, 95% CI 0.95-
2.43, p=0.078) or Ku70 (HR 1.03, 95% CI 0.54-1.96, 
p=0.936), although loss of expression of ATM came close 
to significance.
Table 2: Table of clinicopathological variables and their correlations with gamma-H2AX, ATM 
and Ku70 expression corrected for multiple testing via Bonferroni method
γ-H2AX ATM Ku70
Not 
expressed Expressed P
Not 
expressed Expressed P
Not 
expressed Expressed P
Study arm Placebo 91 89 0.260 71 123 0.084 34 72 0.244Rofecoxib 116 89 56 144 40 58
Chemo No 69 72 0.148 40 96 0.384 24 52 0.282Yes 138 106 87 171 50 78
RXT
No 181 161
0.350
115 236
0.520
68 116
0.539Yes 26 17 12 31 6 14
Dukes stage B 84 91 0.038 54 112 0.914 35 70 0.368C 123 87 73 115 39 60
Gender Female 67 67
0.279
45 94
0.965
29 54
0.743Male 140 111 82 173 45 76
Site Colon 139 112
0.385
85 175
0.786
46 85
0.644Rectum 68 66 42 92 28 45
KRAS status Wild type 125 112
0.590
87 162
0.127
47 77
0.482Mutant 68 54 33 89 23 47
BRAF status Wild type 166 147
0.472
108 217
0.332
63 104
0.236Mutant 27 19 12 34 7 20
MSI status MSS 167 153
0.087
109 224
0.637
66 107
0.085MSI 26 13 11 27 4 17
Age
(95% CI)
-
64.6yrs
(63.4-
65.9)
63.2yrs
(61.8-
64.6)
0.145
65.2yrs
(63.6-
66.7)
63.5yrs
(62.3-
64.6)
0.097
62.6yrs
(60.4-
64.8)
63.5yrs
(61.8-
65.2)
0.517
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DISCUSSION
We have carried out a large-scale investigation of 
the expression of the double strand break repair proteins 
γ-H2AX, ATM and Ku70 in colorectal cancer. We found 
that chromosomal instability was associated with loss of 
expression of Ku70, but that there was no association with 
either γ-H2AX or ATM. It is unclear as to why all DSB 
proteins do not have altered expression in CIN, although 
we note that in a mouse model, hepatocellular carcinomas 
from Ku70 -/- knockout mice displayed greater CIN [13] 
than those from their wild type littermates.
We have also confirmed the findings of Grabsch 
et al [7] who found that reduced ATM expression was 
associated with worse survival in colorectal cancer 
patients receiving adjuvant therapy. We found that the 
association of disease-free survival with ATM expression 
is independent of tumour stage, location, use of chemo/
radiotherapy, gender, KRAS/BRAF mutation status, 
microsatellite instability or chromosomal instability. 
Although we found associations between chemotherapy/
radiotherapy use and disease free survival on univariate 
analysis, this was not seen on multivariate analysis, 
probably due to interactions with our genetic markers. 
The association between CIN and poorer survival 
in colorectal cancer is well documented [14]. Komuro 
et al [9, 15] found an association between higher Ku70 
expression and poorer prognosis in rectal and advanced 
colorectal cancers. Although we did not find a statistically 
significant association between Ku70 expression and 
poorer DFS in our stage II/III cancer cases, there was a 
tendency towards reduced DFS in patients with loss of 
Ku70 expression. Our findings disagree with those of 
Komouro and our study has a larger number of cancers 
and was not restricted to rectal cancers only.  It is possible 
that we did not detect a significant association due to the 
relatively small numbers of samples successfully analysed 
for Ku70 compared with the other markers.
The lack of association in our study between ATM 
or γ-H2AX expression and CIN is of interest. Celeste el 
al [16] demonstrated that H2AX -/- mice demonstrated 
chromosomal instability in embryonic fibroblast cultures 
in a similar pattern to ATM -/- and Ku70/80 -/- mice. Van 
Gent et al [17] demonstrated that CIN can occur either 
because of faulty cell cycle checkpoint regulation or 
failure of DNA repair. ATM and γ-H2AX signal tend to act 
through HR, whereas Ku70 acts via NHEJ. It is possible 
that the type of chromosomal instability seen in colorectal 
cancer is principally associated with NHEJ. 
The induction of DSBs is one mechanism [18] by 
which radiotherapy induces cell death. We have shown that 
loss of γ-H2AX expression has a tendency towards worse 
survival in colorectal cancer in those patients who have 
undergone pre-operative radiotherapy, thus suggesting that 
DSB repair deficient tumours may be non-responders to 
radiotherapy. This conclusion is based on a small sample 
size, and must be regarded as tentative until a larger scale 
study can be set up to study this phenomenon. A similar 
Table 3: Table demonstrating relationship between 
disease free survival and all variables in a multivariate 
survival model, before stepwise correction 
Disease free survival
Variable HR 95% CI P-value
g-H2AX expression
(1=no expression) 0.84 0.42-1.68 0.630
ATM expression
(1=no expression) 0.54 0.27-1.09 0.087
Ku70 expression
(1=no expression) 0.78 0.40-1.54 0.477
Gender (1=male) 1.06 0.49-2.30 0.874
Trial arm (1=Rofecoxib) 0.88 0.43-1.80 0.731
Stage (1=Dukes C) 0.70 0.28-1.72 0.436
Age (years) 0.99 0.96-1.03 0.702
Time from diagnosis to 
recruitment (days) 1.00 0.99-1.01 0.187
Chemotherapy (1=yes) 0.99 0.09-10.53 0.990
Radiotherapy (1=yes) 0.99 0.31-3.18 0.996
Site (1=rectum) 0.75 0.33-1.72 0.502
CIN status (1=CIN+) 1.32 0.65-2.71 0.440
KRAS mutation(1=mutant) 0.78 0.37-1.63 0.509
BRAF mutation (1=mutant) 1.06 0.67-3.09 0.907
MSI status (1=MSI+) 0.55 0.11-2.63 0.450
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phenomenon has been seem in patients undergoing 
chemotherapy with loss of ATM expression within their 
tumours, showing a tendency towards worse survival in 
colorectal cancer.
In conclusion, we have demonstrated an association 
between presence of Ku70 and CIN in colorectal cancer 
and confirmed an association between ATM expression 
and superior DFS. These associations are independent 
of other variables. For Ku70, functional analyses will 
determine whether the association is related to the 
underlying cause of CIN lying in increased DSBs and 
hence NHEJ activation. By comparison, ATM expression 
might be used in the near future as a biomarker of 
prognosis in colorectal cancer.  
SUPPLEMENTARY MATERIAL
Supplementary figures S1-S3 can be found online 
METHODS
Patients and tissue microarray (TMA)
Patients were recruited from the Vioxx in Colorectal 
Cancer study (VICTOR) study [10]. VICTOR was a 
randomised control trial comparing the effect of post-
treatment rofecoxib against placebo in reducing recurrence 
in patients who had undergone a resection of a potentially 
curable stage II or stage III colorectal carcinoma. The 
VICTOR trial initially aimed to recruit 7,000 patients, but 
it was terminated prematurely in 2004 due to the adverse 
cardiovascular risk and mortality associated with COX-
2 inhibitors. In total 2,434 patients were recruited and, 
of those, 978 had tumour blocks and/or blood samples 
available for study. Patients were randomised into two 
groups, one group taking 25mg rofecoxib daily and 
the other placebo. The median duration of rofecoxib 
therapy was 7.4 months. Twenty-four tissue microarrays 
were constructed from tumour and normal tissue from 
each patient. At least three representative 0.6mm cores 
of tumour and one paired 0.6mm core of normal tissue 
(obtained from full thickness normal colon 10cm distal to 
the tumour) were sampled from each patient, as well as at 
least two cores of metastasis and/or lymph node if present. 
For immunohistochemistry, serial 4μM sections were cut 
from each block. 
Immunohistochemistry
For gamma-H2AX, a mouse monoclonal antibody 
was used (Abcam ab22551) at 1:50 dilution and 1 
hour incubation at room temperature, for ATM a rabbit 
monoclonal antibody was used (Abcam ab32420) at 1:50 
dilution with overnight incubation at 4oC, and for Ku70 
a mouse monoclonal antibody (Abcam ab2172) at 1:50 
dilution with overnight incubation at 4oC. A standard 
indirect immunohistochemistry (IHC) technique was 
used for all three antibodies. The tissue section was 
dewaxed in xylene and rehydrated in graded alcohol 
solutions.  Endogenous peroxidase activity was blocked 
by immersing the slides in 1% H
2
O
2
 in methanol for 15 
minutes. Heat-induced epitope retrieval was then carried 
out in a pressure cooker using 1L of citrate buffer solution 
(pH 6) boiled at full pressure for 3 minutes. Slides were 
then incubated in horse serum (Vectalabs) for 30 minutes 
as a blocking step and washed with PBS. Next, the slides 
were incubated with the primary antibody, washed with 
PBS and a secondary biotinylated horse anti-mouse 
antibody (Vectalabs) was applied at room temperature 
for 1 hour. Slides were then washed with PBS, incubated 
with an avidin-biotin-horseradish peroxidase solution 
(VectaStain ABC Elite) for 1 hour and then washed 
again with PBS. Slides were then stained using DAB 
solution (Sigma Fast-DAB) for 2 minutes (experimentally 
determined), washed with PBS and counterstained 
with haemotoxylin. Sections were finally dehydrated 
in serial alcohol solutions and coverslips were applied. 
Positive controls consisted of human breast carcinoma 
(ATM), human tonsil tissue (Ku70) and human tonsillar 
lymphoma (g-H2AX) as recommended by the antibody 
manufacturer’s datasheet. Negative controls consisted 
of tissue through which all steps were performed except 
application of the primary antibody. 
A Carl-Zeiss NanoZoomer scanning microscope 
was used to create a digital image of each slide at 40x 
optical magnification. Images were transferred to a 
Genetix SlidePath TMA management system. Expression 
scoring was carried out by two independent observers 
(MP and MMcG) and compared to the expression seen 
in the positive control. As there were three cores for each 
tumour, each core was scored separately and the average 
expression between cores for each tumour used. For 
g-H2AX, expression was dichotomised into either no 
nuclear expression (absent) or nuclear expression (>1+ 
nucleus per core).   For ATM and Ku70/80, expression 
was graded as either reduced/absent (compared to normal 
mucosa) or present. If there was disagreement between 
observers for the average score across all the cores, the 
higher expression score was used as the assumption in 
this study was that loss of expression was more significant 
and so using the sample with least expression would 
skew the results. Correlation of scores between the 
independent observers was calculated using Spearman’s 
Rank correlation coefficient.  Representative images for 
IHC are shown in the supplementary materials as figures 
S1-S3 (available on-line)
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Tumor genotyping
Image cytometry to analyse CIN was carried out in 
a sub-set of tumours as described by Leedham et al [11]. 
We defined CIN as a modal DNA content that was distinct 
from and greater than the diploid peak in non-tumour 
cells. Ploidy was called based on the ABCDE technique 
of Buhmeida et al [12]. DNA for tumour genotyping was 
obtained from 4μM formalin fixed, paraffin embedded 
sections from the same block from which the TMA core 
was originally taken. Needle dissection was carried 
out under light microscopy to minimise contaminating 
normal tissue. Dissected tissue then underwent Proteinase 
K digestion, purification using Qiagen DNEasy clean-
up kit and underwent quality control using a NanoDrop 
spectrophotometer,  Microsatellite instability (MSI) status 
was ascertained using BAT25/BAT26 primers in a standard 
PCR reaction. MSI was said to be present if additional 
alleles were present compared to normal controls. KRAS 
and BRAF mutations were identified by direct sequencing 
(primer sequences and conditions available on request). 
Statistical analysis
To compare gamma-H2AX, ATM and Ku70 
expression with ploidy, Fisher’s exact and X2 tests were 
used. To compare survival time data for patients, Kaplan-
Meier plots for survival were constructed, and for overall 
survival modelling, univariate and multivariate Cox 
proportional hazards survival models were constructed. 
The validity of the proportional hazards assumptions were 
confirmed using a proportional hazards plot and by testing 
Schoenfeld residuals (details available on request).  
Available variables for multivariate analysis were 
age, gender, Dukes stage, tumour location (colon or 
rectum), chemotherapy, radiotherapy, CIN status, KRAS 
mutation, BRAF mutation and MSI. 
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